CorMedix Inc. (CRMD) CEO reports option exercise and equity transactions

Rhea-AI Filing Summary

CorMedix Inc. Chief Executive Officer Joseph Todisco, who also serves as a director, reported equity award-related transactions in the company’s common stock. On 01/16/2026, he exercised a stock option for 29,585 shares of common stock at an exercise price of $3.38 per share from an option originally granted on 5/10/2022, increasing his directly held common stock to 521,664 shares and leaving 411,245 options outstanding. The filing also reports transactions coded “F” on 01/12/2026 for 17,417 shares at $7.15 and on 01/17/2026 for 22,665 shares at $6.78, after which he directly held 492,079 and then 498,999 common shares. A footnote explains that the option exercise price was paid in cash and that no sales of stock were made. Another footnote states the Form 4 is being reported late due to an inadvertent administrative error.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Todisco Joseph

(Last) (First) (Middle)

C/O CORMEDIX INC.

300 CONNELL DRIVE, SUITE 4200

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026(1)		F		17,417	D	$7.15	492,079	D
Common Stock	01/16/2026		M		29,585(2)	A	$3.38	521,664	D
Common Stock	01/17/2026		F		22,665	D	$6.78	498,999	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$3.38	01/16/2026		M			29,585	(3)	05/09/2032	Common Stock	29,585	$0	411,245	D

Explanation of Responses:

1. This transaction is being reported late due to an inadvertent administrative error.

2. The Reporting Person acquired stock through the exercise of options granted on 5/10/2022. The Reporting Person paid the exercise price in cash. No sales of stock were made.

3. These options were granted on 5/10/2022. These options vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CorMedix Inc. (CRMD) report for CEO Joseph Todisco?

The filing reports that Chief Executive Officer and director Joseph Todisco exercised stock options for 29,585 shares of CorMedix Inc. common stock on 01/16/2026 and reported additional equity award-related transactions coded “F” on 01/12/2026 and 01/17/2026.

How many CorMedix (CRMD) shares did the CEO acquire through option exercise and at what price?

On 01/16/2026, the CEO exercised a stock option (right to buy common stock) for 29,585 shares at an exercise price of $3.38 per share, from an option grant dated 5/10/2022.

How many CorMedix (CRMD) shares does the CEO hold after these transactions?

Following the 01/16/2026 transaction coded “M,” the CEO directly held 521,664 shares of CorMedix common stock. After the subsequent 01/17/2026 transaction coded “F,” he directly held 498,999 shares.

Were any CorMedix (CRMD) shares sold in these insider transactions?

A footnote states that the reporting person acquired stock through the exercise of options granted on 5/10/2022, paid the exercise price in cash, and that no sales of stock were made.

What do the Form 4 transactions coded "F" and "M" mean for CorMedix (CRMD)?

In this filing, code "M" reflects the exercise of a stock option for 29,585 shares at $3.38. Transactions coded "F" on 01/12/2026 for 17,417 shares at $7.15 and on 01/17/2026 for 22,665 shares at $6.78 are reported in connection with his common stock holdings, and the footnote clarifies that no sales of stock were made.

Why does the CorMedix (CRMD) Form 4 mention a late filing?

An explanation of responses states that this transaction is being reported late due to an inadvertent administrative error, indicating the timing issue relates to filing, not the substance of the transactions.

What are the terms of the CorMedix (CRMD) stock options referenced in the Form 4?

The options were granted on 5/10/2022 and vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through each vesting date. After the reported exercise, 411,245 options remained beneficially owned.